The drug is being developed by the Chinese biotech Abbisko Therapeutics Co. Merck KGaA holds commercial license for Pimicotinib in Chinese mainland, Hong Kong, Macau, and Taiwan, it said.

with very low rates of discontinuation due to treatment-related adverse events Pimicotinib is being developed by Abbisko Therapeutics Co., Ltd.; Merck holds commercial license for pimicotinib in ...

On Thursday, Merck & Co Inc (NYSE:MRK) reported third-quarter sales of $16.66 billion, up 4% year over year, beating the ...

Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...

Despite challenges in GARDASIL sales, Merck & Co Inc (MRK) reports robust growth in KEYTRUDA and new product launches, ...

Welcome to the Merck & Company Q3 sales and earnings conference call. [Operator instructions] This call is being recorded.

Merck (MRK) is set to announce Q3 earnings on October 31st. Analysts expect a profit of $1.57 per share on revenue of $16.51B ...

Merck, a leading science and technology company, today announced a € 70 million expansion of its ADC manufacturing ...

Beyond Gardasil, Goldman Sachs highlights a solid lineup of positives for Merck, including robust performance from key franchises like Keytruda and promising momentum from both commercial products ...

Shares in Merck & Co were more than 2% lower as New York trading entered its latter half on Thursday. The US pharma giant ...

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, announced a $76 million expansion of its ADC manufacturing ...